id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-319851-mhnp42xo	Cao, Xiaoling	Authors’ response to letter by Fogacci, Borghi and Cicero, “Misinterpreting data in lipidology in the era of COVID-19”	2020-07-09		.txt	text/plain	765	48	54	Furthermore, in a longitudinal study at another hospital in Wuhan, we examined lipid profiles from inpatients (n=21) before viral infection, on admission, and during the course of their illness. 2 Collectively, this evidence demonstrates that decreases in LDL-c levels are associated with severity of COVID-19 and reflect the disease course. We are well aware of the concerns raised by Drs. Fogacci, Borghi and Cicero about the potential effects of lipid-lowing medications being given routinely to those patients with cardiovascular disorders (CVD) or diabetes on their LDL-c levels on admission. In U.S., Italy and other nations, as many as half or more of patients with CVD or diabetes would be taking statins prior to onset of COVID-19 and many of them would continue until the time of hospital admission. 3, 4 Therefore, hypolipidemia in COVID-19 patients most likely results from SARS-CoV-2 infection and associated hyper-inflammation, not lipid-lowering medications.	./cache/cord-319851-mhnp42xo.txt	./txt/cord-319851-mhnp42xo.txt